Diranersen showed robust tau reduction and cognitive benefits in early Alzheimer's, with the 60 mg twice-yearly dose emerging as optimal despite no clear dose-response. Safety was favorable, and high patient retention supports advancing to phase III, with further biomarker and subgroup analyses planned.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.